Cargando…

Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer’s disease: A systematic review

BACKGROUND: Lecanemab is the latest monoclonal antibody that targets beta-amyloid approved exclusively for treatment of Alzheimer’s disease with mild cognitive impairment or mild dementia. This article aims to provide a systematic review of the efficacy, and safety of lecanemab in slowing clinical d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chowdhury, Selia, Chowdhury, Nurjahan Shipa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617290/ https://www.ncbi.nlm.nih.gov/pubmed/37902139 http://dx.doi.org/10.1177/03946320231209839

Ejemplares similares

Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab
por: Shi, Mingchao, et al.
Publicado: (2022)

Omicron variant of SARS-CoV-2 infection elicits cross-protective immunity in people who received boosters or infected with variant strains
por: Chowdhury, Selia, et al.
Publicado: (2022)

Anti-amyloid-β Monoclonal Antibodies as Promising Disease-Modifying Therapies in Alzheimer’s Disease: A Focus on Aducanumab, Lecanemab, Crenezumab, Gantenerumab and Solanezumab
por: Melo, V. S. D., et al.
Publicado: (2023)

Lecanemab reduces brain amyloid-β and delays cognitive worsening
por: Knopman, David S.
Publicado: (2023)

Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies
por: Rygiel, Katarzyna
Publicado: (2016)

The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint
por: Jönsson, Linus, et al.
Publicado: (2023)

Lecanemab: A hope in the management of Alzheimer’s disease
por: Thakkar, Nandita, et al.
Publicado: (2023)

Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise
por: van Dyck, Christopher H.
Publicado: (2017)

Reply: Unblinding in the lecanemab trial in Alzheimer’s disease
por: Hardy, John, et al.
Publicado: (2023)

Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease
por: Söderberg, Linda, et al.
Publicado: (2022)

Can Anti–β-amyloid Monoclonal Antibodies Work in Autosomal Dominant Alzheimer Disease?
por: Imbimbo, Bruno P., et al.
Publicado: (2020)

Effect of Lecanemab and Donanemab in Early Alzheimer’s Disease: Mechanistic Interpretation in the Amyloid Cascade Hypothesis 2.0 Perspective
por: Volloch, Vladimir, et al.
Publicado: (2023)

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
por: Swanson, Chad J., et al.
Publicado: (2021)

Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease
por: Hayato, Seiichi, et al.
Publicado: (2022)

Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
por: Swanson, Chad J., et al.
Publicado: (2022)

Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials
por: Qiao, Yue, et al.
Publicado: (2023)

Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics
por: Cummings, Jeffrey
Publicado: (2023)

Editorial: A Time of Transition of Alzheimer's Disease in the Advent of Anti-Amyloid Monoclonal Antibodies
por: Tousi, Babak, et al.
Publicado: (2021)

The Potential Economic Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

Estimated Societal Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2023)

The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials
por: Wu, Wenxue, et al.
Publicado: (2023)

FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective
por: Verger, Antoine, et al.
Publicado: (2023)

Predicting the Societal Value of Lecanemab in Early Alzheimer’s Disease in Japan: A Patient-Level Simulation
por: Igarashi, Ataru, et al.
Publicado: (2023)

Novel Oral CGRP Receptor Antagonist Atogepant in the Prevention of Migraine
por: Chowdhury, Selia, et al.
Publicado: (2023)

Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

Amyloid-Lowering Monoclonal Antibodies for the Treatment of Early Alzheimer’s Disease
por: Leisher, Solana, et al.
Publicado: (2023)

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
por: Bateman, Randall J., et al.
Publicado: (2022)

Effectiveness and safety of monoclonal antibodies against amyloid-beta vis-à-vis placebo in mild or moderate Alzheimer's disease
por: Hao, Ying, et al.
Publicado: (2023)

ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease
por: Honig, Lawrence S., et al.
Publicado: (2023)

Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta
por: Rofo, Fadi, et al.
Publicado: (2021)

Prophylaxis and Treatment of Alzheimer's Disease by Delivery of an Adeno-Associated Virus Encoding a Monoclonal Antibody Targeting the Amyloid Beta Protein
por: Shimada, Masaru, et al.
Publicado: (2013)

Association of Guillain–Barré syndrome following COVID-19 vaccination
por: Chowdhury, Selia, et al.
Publicado: (2023)

Reply: Lecanemab: turning point, or status quo? An ethics perspective
por: Hardy, John, et al.
Publicado: (2023)

Generation and Characterization of Anti-AA Amyloid-Specific Monoclonal Antibodies
por: Wall, Jonathan S., et al.
Publicado: (2011)

Do anti-amyloid beta protein antibody cross reactivities confound Alzheimer disease research?
por: Hunter, Sally, et al.
Publicado: (2017)

Human antibodies reactive with beta-amyloid protein in Alzheimer's disease
Publicado: (1993)

Antibody-Mediated Clearance of Brain Amyloid-β: Mechanisms of Action, Effects of Natural and Monoclonal Anti-Aβ Antibodies, and Downstream Effects
por: Loeffler, David A.
Publicado: (2023)

Anti-amyloid: An antibody to cure Alzheimer’s or an attitude
por: Osborne, Olivia M., et al.
Publicado: (2023)

Comparative Study of Safety and Efficacy of Angiotensin-Receptor Blockers and Anti Amyloid-ß Monoclonal Antibodies for the Treatment of Alzheimer’s Disease: A Systematic Review
por: Shahid, Kamran, et al.
Publicado: (2023)

Advancing (89)Zr-immuno-PET in neuroscience with a bispecific anti-amyloid-beta monoclonal antibody - The choice of chelator is essential
por: Wuensche, Thomas E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1mnm0c7021a6fh59t2487pedof